Literature DB >> 31210442

Mitochondrial Polymorphisms, in The D-Loop Area, Are Associated with Brain Tumors.

Donya Altafi1, Soha Sadeghi2, Hamed Hojatian2, Maryam Torabi Afra2, Safoura Pakizeh Kar3, Mojtaba Gorji4, Massoud Houshmand5,6.   

Abstract

OBJECTIVE: This study was carried out to evaluate the relationship between mtDNA D-loop variations and the pathogenesis of a brain tumor.
MATERIALS AND METHODS: In this experimental study, 25 specimens of brain tumor tissue with their adjacent tissues from patients and 454 blood samples from different ethnic groups of the Iranian population, as the control group, were analysed by the polymerase chain reaction (PCR)-sequencing method.
RESULTS: Thirty-six variations of the D-loop area were observed in brain tumor tissues as well as the adjacent normal tissues. A significant difference of A750G (P=0.046), T15936C (P=0.013), C15884G (P=0.013), C16069T (P=0.049), T16126C (P=0.006), C16186T (P=0.022), T16189C (P=0.041), C16193T (P=0.045), C16223T (P=0.001), T16224C (P=0.013), C16234T (P=0.013), G16274A (P=0.009), T16311C (P=0.038), C16327T (P=0.045), C16355T (P=0.003), T16362C (P=0.006), G16384A (P=0.042), G16392A (P=0.013), G16394A (P=0.013), and G16477A (P=0.013) variants was found between the patients and the controls.
CONCLUSION: The results indicated individuals with C16069T [odds ratio (OR): 2.048], T16126C (OR: 2.226), C16186T (OR: 3.586), G16274A (OR: 4.831), C16355T (OR: 7.322), and T16362C (OR: 6.682) variants with an OR more than one are probably associated with a brain tumor. However, given the multifactorial nature of cancer, more investigation needs to be done to confirm this association. Copyright© by Royan Institute. All rights reserved.

Entities:  

Keywords:  Brain Tumor; D-Loop; Mitochondrial DNA

Year:  2019        PMID: 31210442      PMCID: PMC6582428          DOI: 10.22074/cellj.2019.5947

Source DB:  PubMed          Journal:  Cell J        ISSN: 2228-5806            Impact factor:   2.479


Introduction

Brain tumors refer to all tumors in the central spinal canal or inside the cranium. All brain tumors are innately serious and fatal because of their infiltrative and invasive features in the confines of the intracranial cavity. According to the American Cancer Society, death estimation of Brain and other nervous system tumors is 6,150 (2%) per 100,000 in 2013. In 2013, 1310 cancer deaths amongst children between 0 to 14 years old were reported. Approximately, 25% of all cancers in children are due to brain and other central nervous system tumors (1-3) . The human mitochondrial DNA (mtDNA) is a 16,569 base-pair-long double-strand DNA. Mitochondrial genome codes thirteen pivotal polypeptides of the respiratory chain enzyme complexes, which are located in the inner membrane of the mitochondria, along with two ribosomal RNAs (rRNAs) and twenty-two transfer RNAs (tRNAs) that are crucial for protein synthesis and intramitochondrial translation, respectively (4). There are 103 to 104 copies of mtDNA per human cell (5). A 1.1 kb of noncoding displacement loop (D-loop) region is situated between the aforementioned genes. This region consists of heavy-strand and light-strand promoter regions which are essential for the mitochondrial transcription and replication process (4, 6, 7). Due to insufficient DNA repair mechanisms, the absence of protective histone proteins, and a considerable level of the reactive oxygen species (ROS) production during oxidative phosphorylation (OXPHOS), mitochondrial DNA is susceptible to oxidative damage and carries significantly more mutations than nuclear DNA. In mtDNA, oxidative damages and the subsequent mutations can accumulate at a rate of 10-fold faster than nuclear DNA (8). In the past, a myriad of somatic mtDNA mutations, including insertions, deletions, point mutations, and altered mtDNA copy numbers, have been detected in numerous human cancers (9). In the mitochondrial genome, some of these mutations lead to functional alterations in its encoded proteins or missense mRNA transcription (10). In the coding region, the common deletion region (CD) (4,977 bp deletion) is the most frequent (11). It has been shown that large deletions in the mitochondrial genome are accumulated in subjects with heteroplasmic mtDNA mutations and healthy elders (12). The somatic variations in the D-loop area may be associated with the diminution of mtDNA copy numbers as well (13). The D-loop area of Mitochondrial DNA is a polymorphic region (14). The most of the mtDNA mutations occurring in D-loop are linked to human malignancies (13). Therefore, studying mtDNA mutations in various tumor cells is pivotal for understanding the relationship between mtDNA D-loop mutations and the initiation and progression of a tumor (15).

Materials and Methods

Subjects

In this experimental study, 25 samples of brain tumors and adjacent tissues (2 women and 23 men in the age range of 28 to 70 years old) were collected (Table 1). Furthermore, 454 blood samples from healthy controls were included; these samples are from 100 random individuals, belonging to17 ethnicities of the Iranian population. All of the samples were collected from the Tehran Special Medical Center. Tumor tissues and adjacent ones were quickly frozen by liquid nitrogen and transferred to a -80˚C freezer. The cancer diagnosis was confirmed via histological analysis. In the control group, the exclusion criterion was metabolic diseases, history of cancer, and any mitochondrial DNA related diseases which might affect the mtDNA.
Table 1

Age and histological features of brain tumors in patients


SampleAgeClinical dataDiagnosisGender

153Left frontal brain tumorAstrocytomaMale
253Right fronto-temporal brain tumorGiant Cell GlioblastomaMale
340A right parieto-occipital brain tumorOligodendrogliomaMale
448Right temporal brain tumorAstrocytomaMale
558Left frontotemporal brain tumorAstrocytomaMale
633Intraventicular brain tumorEpendymomaMale
756Right temporal brain tumorAstrocytomaMale
851Right temporal brain tumorGlioblastoma multiformMale
955Left temporal brain tumorAstrocytomaMale
1057Right frontoparietal brain tumorGlioblastoma multiformMale
1165Left temporal brain tumorAstrocytomaMale
1242Right parieto-occipital brain tumorOligodendrogliomaMale
1370Right frontoparietal brain tumorGlioblastoma multiformFemale
1454Right frontal brain tumorGlioblastoma multiformMale
1558A cerebral tumorGlioblastoma multiformMale
1653Right temporal brain tumorGlioblastoma multiformMale
1763Right temporal brain tumorGlioblastoma multiformMale
1840A cerebral tumorGlioblastoma multiformMale
1928Left frontal brain tumorGlioblastoma multiformMale
2055A right frontoparietal brain tumorOligodendrogliomaMale
2163Right frontal brain tumorGlioblastoma multiformMale
2232Left frontal cerebral tumorGlioblastoma multiformMale
2332Cerebral tumorAstrocytomaMale
2456Right temporal brain tumorAstrocytomaFemale
2536Left temporal brain tumorAstrocytomaMale

Age and histological features of brain tumors in patients

DNA extraction

Genomic DNA of the tumor and the adjacent tissues were isolated by DNA extraction kit (Qiagen, Netherlands) and blood samples of the controls. which were collected in Ethylenediaminetetraacetic acid (EDTA)-containing tubes, were extracted using Diatom DNA extraction kit (Gene Fanavaran, Iran) and their quantity and quality were analyzed by NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific) and agarose gel electrophoresis, respectively.

Mitochondrial D-loop genotyping

Primers for amplifying of the mtDNA D-loop region were adapted from Seyedhassani et al. (16) and Shakhssalim et al. (17). The volume of a PCR reaction was 25 μl and contained 50- 100 ng of the DNA, 0.8 μl of the primers, 0.8 μl of MgCl2, 0.5 μl of dNTPs 10 mM, 2.5 μl of PCR buffer (10X), and 0.3 μl of Taq DNA polymerase (Roche Applied Sciences, Germany). Moreover, the PCR procedure was carried out according to the following protocol: pre-denaturation phase (5 minutes at 94˚C), followed by 35 cycles of the shorter denaturation phase (50 seconds at 94˚C), annealing step (50 seconds at 55˚C), the extension step (50 seconds at 72˚C), The final stage is the extension phase for 10 minutes at 72˚C. Each amplified fragment subsequently was sequenced using an ABI PRISM 3730 sequence analyzer (Macrogen, Korea). The acquired sequencing data were evaluated using Finch TV.

Statistical analysis

Finch TV version 1.4.0 was used to edit and align the sequences. The NCBI blast was used as a reference. The statistical analysis was carried out using IBM SPSS statistics for windows, version 24.0 (IBM Corp., Armonk, NY, USA). The chi-square was used to evaluate the deviation from the Hardy-Weinberg equilibrium. This association between a brain tumor and D-loop variants was evaluated using SPSS version 22. A P<0.05 was considered statistically significant

Results

In the present study, tissue samples from 25 subjects with brain tumors and 454 blood samples from the control group were genotyped for D-loop region variants. The subsequent results showed 36 variations in the D-loop area (Table 2), most of which were already reported under MITOMAP. One hundred and fifteen variations of the D-loop region were found in the control groups (Table 3). However, 34 mutations in the patients and 103 mutations in the control were reported in advance, and 2 mutations in the patients and 12 mutations in the control were novel mutations (Table 4). All variations were single nucleotide substitutions and the majority of them were C→T. (33.33%) T→C (30.55%) G→A (22.22%) A→C (2.77%) C→G (2.77%). The D-loop region variant distributions in the controls and the patients are shown in Table S1 (See Supplementary Online Information at www. celljournal.org). The significant associations between variants and brain tumor risk (P<0.05) are shown in Table 5.
Table 2

List of D-loop region variants in the patient group (tissue sample)



A152GT195CT204CG207AA263GT489CA750GC15884GG15928AT15936C*
C16069TT16126CG16145AC16148TT16172CC16186TT16189CC16193TC16223TT16224C
C16234TC16256TC16261TC16270TG16274AC16292TT16311CA16318CC16327TC16355T
T16362CG16384AG16392AG16394AG16477AT16519C

*; Shows unreported mutations near the D-loop region.

Table 3

List of D-loop region variants in control group (blood sample)



A152GT195CT204CG207AA263GT489CA750GA15908GT15924CC15927T
C15928TG15946AG16004C*A16017GA16069GG16071AA16075GC16084TA16086GA16087G*
A16093GG16095AG16114AG16124A*A16126GA16128G*C16129TG16131A*C16145TG16148A
C16149TG16150AT16162CT16163CA16172GG16174AG16176AA16177GA16179GG16184A
G16186AC16187TA16189GG16192AG16193AG16197AG16201AT16203CA16209GA16217G
A16223GG16233AG16236AG16242AA16243GG16245AA16248GA16249GG16256AG16257A
G16259AG16261AG16262AT16265CC16266TG16270AA16271GA16272GC16274TG16278A
A16286GG16287AA16289GG16290AG16291AG16292AT16293GG16294AG16295AG16296A
A16299GA16304GT16309CA16311GG16315A*T16316CT16318AC16319TA16323GA16325G
A16334GC16339TA16342GT16343CA16344G*A16352GG16354TG16355AA16356GA16359G
G16360AA16362GG16364AC16390TC16391TC16398TT16399CA16468GG16478CG16481A*
G16488AT16497CT16519CC16526TG16527A

*; Shows unreported variations in D-loop region and adjacent sequences.

Table 4

List of unreported variants in patient and control groups



A15499GG16004CA16087GG16124AA16128GG16131AA16179GG16233AA16286GG16315A
A16344GG16481A    

List of D-loop region variants in the patient group (tissue sample) *; Shows unreported mutations near the D-loop region. List of D-loop region variants in control group (blood sample) *; Shows unreported variations in D-loop region and adjacent sequences. List of unreported variants in patient and control groups The variations statistical analysis and associations between them whit brain tumour risk a; 0 blocks (0.0%) have considered rate less than 5. The minimum envisaged rate is 31.50.

Discussion

Studies have shown that the accumulation of mitochondrial DNA variations and mitochondrial instability contributes to several diseases, including cancer. The mitochondrial D-loop area has pivotal functions in transcription, replication, and mtDNA organization. Presence of two critical factors makes mitochondrial genome prone to different mutations: ROS and low-level of DNA repair system in mitochondria (18). However, the D-loop region is even more susceptible to the mutations than the rest of the human mitochondrial genome (12). It has been demonstrated that the expansion of poly-C repeats in highly variable regions (HVR), adjacent to the D-loop and tRNA phenylalanine, increases the copy number; homoplasmy and loss of mitochondrial heteroplasmy act like cancer suppressor genes and will cause brain cancer and other cancers in humans (19). Recent studies demonstrate that mitochondrial D-loop mutations play an important role in Huntington’s disease (20), as well as various cancers, including brain tumors. Consequently, in this survey was hypothesised that particular mutations in the D-loop region might be related with brain tumor risk. Twenty-five tissue samples of brain tumors were assessed. As it is not possible to use brain tissues of healthy individuals, we used 454 blood samples as the control. A significant difference between the cancer tissue and the healthy tissue was observed. Also, we studied the mutations reported in MITOMAP in more detail. It has been proven that D-loop variants are associated with different disease: T195C variant with glaucoma (21) and G15884C variant with pancreatic cancer (22) and G15928A with MS, recurrent idiopathic abortion and AD (23) and C16069T with bladder cancer (24) and T16126C with Huntington’s disease (20) and C16172T with head and neck cancer (25) and T16189C with prostate cancer (26) and C16193T with ovarian cancer (27) and C16223T with cancer, and Huntington’s (20) and G16274A linked to prostate cancer (28) and C16292T related with breast and ovarian cancer (27) and T16311C with prostate cancer (28) and T16519C with glioblastoma, migraines (29). Although T204C (30), G207A (28), A263G (31), T489C (25), A750G (21), G16145A (16), C16148T (32), C16186T (33), T16224C, C16234T, C16256T (34), C16270T, C16261T (35, 36), C16327T (37), C16355T (38), T16362C (39), G16384A (16), G16392A, G16394A, G16477A (40), were associated with various cancers and were reported in MITOMAP but they were not associated with the disease. In this experimental study, A750G, T15936C, C15884G, C16069T, T16126C, C16186T, T16189C, C16193T, C16223T, T16224C, C16234T, G16274A, T16311C, C16327T, C16355T, T16362C, G16384A, G16392A, G16394A, G16477A variants had statistically significant different frequencies between patient and control groups. Thus, it seems that they are associated with brain tumors. Among the mentioned polymorphisms, C16069T, T16126C, C16186T, G16274A, C16355T, and T16362C had a greater odd ratio (OR) than the rest. C16355T polymorphism had the most significant association with the disease in risk. It should be noted that A152G, T204C, G207A, A263G, T489C, A750G, G15928A, G16145A, C16148T, T16172C, C16256T, C16261T, C16270T, C16292T, A16318C, and T16519C polymorphisms were not associated with the disease risk. Although, they have significant roles in other disease pathogenesis as they have been reported on MIT OMAP. In Lorr ethnicity, T15936C, C15884G, G15928A, T16126C, C16148T, T16172C, C16186T, C16186T, C16193T, C16223T, T16224C, C16234T, C16256T, C16292T, T16311C, T16362C, G16384A, G16392A, G16394A, and G16477A polymorphisms were associated with brain tumors. T16126C and T16362C polymorphisms had a higher odds ratio than the rest which indicates they are more associated with this disease. C16069T, G16145A, T16189C, C16261T, C16270T, A16318C, C16327T, and T16519C polymorphisms were not associated with the disease in Lorr ethnicity. However, the mentioned polymorphisms are associated with other disease pathogenesis as they reported on MITOMAP. In Fars ethnicity, T15936C, C15884G , C16069T, T16126C, C16193T, T16224C, C16234T, C16261T, C16292T, C16327T, C16355T, G16384A, G16392A,G16394A, and G16477A variants were associated with the disease, C16069T, T16126C, C16186T, G16274A, C16355T, and T16362C polymorphisms had greater odds ratio than the rest, and G15928A, G16145A, C16148T, T16172C, C16186T, T16189C, C16223T, C16256T, C16270T, G16274A, T16311C, A16318C, T16362C, and T16519C variants were not associated with the disease.

Conclusion

Base on the odds ratio result, C16069T, T16126C, C16186T, G16274A, C16355T, and T16362C alterations were significantly associated with brain tumor. Among these variants, C16355T with odds ratio 7.322 was the strongest one.
Table 5

The variations statistical analysis and associations between them whit brain tumour risk


Odds ratio Chi-square testsP valueControl (%)Patients (%) Variant

0.946.186a0.01306.25T15936C
0.946.186a0.01306.25C15884G
10.000a16.386.25G15928A
2.0483.854a0.04913.8725C16069T
2.2267.490a0.00630.8350T16126C
1.571.339a0.24712.9918.75G16145A
1.5320.421a0.5163.966.25C16148T
1.5320.421a0.5164.186.25T16172C
3.5865.207a0.0223.5212.5C16186T
0.4574.190a0.04122.912.5T16189C
6.3193.701a0.0451.326.25C16193T
0.31810.351a0.00131.7112.5C16223T
0.946.186a0.0130.226.25T16224C
0.946.186a0.0130.886.25C16234T
1.5320.421a0.5164.46.25C16256T
1.8982.510a0.11310.5718.75C16261T
2.0641.047a0.3062.66.25C16270T
4.8316.793a0.0092.8612.5G16274A
2.0641.047a0.3062.646.25C16292T
0.3624.310a0.03814.756.25T16311C
1.2130.96a0.7564.626.25A16318C
6.3193.701a0.0450.666.25C16327T
7.3228.721a0.0032.212.5C16355T
6.6827.680a0.0069.2518.75T16362C
2.3724.153a0.04206.25G16384A
0.946.186a0.0130.226.25G16392A
0.946.186a0.01306.25G16394A
0.946.186a0.01306.25G16477A
0.7471.017a0.31362.5556.25T16519C
1.0470.023a0.8730.832A152G
0.52.94a0.0821.412T195C
1.370.47a0.489.312T204C
1.811.45a0.22712G207A
000100100A263G
1.340.741a0.3819.124T489C
0.393.979a0.04693.384A750G

a; 0 blocks (0.0%) have considered rate less than 5. The minimum envisaged rate is 31.50.

  40 in total

1.  Hypervariable sites in the mtDNA control region are mutational hotspots.

Authors:  M Stoneking
Journal:  Am J Hum Genet       Date:  2000-08-30       Impact factor: 11.025

2.  Comprehensive association testing of common mitochondrial DNA variation in metabolic disease.

Authors:  Richa Saxena; Paul I W de Bakker; Karyn Singer; Vamsi Mootha; Noel Burtt; Joel N Hirschhorn; Daniel Gaudet; Bo Isomaa; Mark J Daly; Leif Groop; Kristin G Ardlie; David Altshuler
Journal:  Am J Hum Genet       Date:  2006-05-24       Impact factor: 11.025

3.  Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age.

Authors:  M Corral-Debrinski; T Horton; M T Lott; J M Shoffner; M F Beal; D C Wallace
Journal:  Nat Genet       Date:  1992-12       Impact factor: 38.330

Review 4.  Mitochondrial mutations in cancer.

Authors:  M Brandon; P Baldi; D C Wallace
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

5.  Extensive somatic mitochondrial mutations in primary prostate cancer using laser capture microdissection.

Authors:  Junjian Z Chen; Neriman Gokden; Graham F Greene; Perkins Mukunyadzi; Fred F Kadlubar
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

6.  Nucleotide sequence variation is frequent in the mitochondrial DNA displacement loop region of individual human tumor cells.

Authors:  Haruko Yoneyama; Toshiko Hara; Yo Kato; Takao Yamori; Etsuko T Matsuura; Katsuro Koike
Journal:  Mol Cancer Res       Date:  2005-01       Impact factor: 5.852

7.  Remarkable infidelity of polymerase gammaA associated with mutations in POLG1 exonuclease domain.

Authors:  R Del Bo; A Bordoni; M Sciacco; A Di Fonzo; S Galbiati; M Crimi; N Bresolin; G P Comi
Journal:  Neurology       Date:  2003-10-14       Impact factor: 9.910

8.  Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications.

Authors:  J S Carew; Y Zhou; M Albitar; J D Carew; M J Keating; Peng Huang
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

9.  Mitochondrial DNA mutations in renal cell carcinomas revealed no general impact on energy metabolism.

Authors:  D Meierhofer; J A Mayr; K Fink; N Schmeller; B Kofler; W Sperl
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

10.  Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma.

Authors:  P H Yin; H C Lee; G Y Chau; Y T Wu; S H Li; W Y Lui; Y H Wei; T Y Liu; C W Chi
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

View more
  1 in total

Review 1.  Mitochondrial DNA Alterations in Glioblastoma (GBM).

Authors:  Mariceli Baia Leão Barros; Danilo do Rosário Pinheiro; Bárbara do Nascimento Borges
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.